This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Marrone Bio Innovations Future Growth
Future criteria checks 2/6
Key information
71.8%
Earnings growth rate
77.0%
EPS growth rate
Chemicals earnings growth | 15.2% |
Revenue growth rate | 25.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions
Jul 11Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook
Aug 21Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future
Apr 08Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?
Mar 13What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?
Feb 15Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain
Jan 25When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?
Jan 04Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?
Dec 09Marrone Bio Innovations, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 90 | N/A | N/A | N/A | 1 |
12/31/2023 | 71 | -4 | N/A | N/A | 2 |
12/31/2022 | 56 | -16 | N/A | N/A | 3 |
3/31/2022 | 44 | -21 | -15 | -13 | N/A |
12/31/2021 | 44 | -17 | -12 | -10 | N/A |
9/30/2021 | 41 | -15 | -16 | -14 | N/A |
6/30/2021 | 40 | -17 | -16 | -14 | N/A |
3/31/2021 | 40 | -16 | -17 | -15 | N/A |
12/31/2020 | 38 | -20 | -18 | -16 | N/A |
9/30/2020 | 37 | -26 | -15 | -14 | N/A |
6/30/2020 | 35 | -36 | -21 | -18 | N/A |
3/31/2020 | 30 | -40 | -22 | -20 | N/A |
12/31/2019 | 29 | -37 | -22 | -21 | N/A |
9/30/2019 | 28 | -33 | -20 | -19 | N/A |
6/30/2019 | 27 | -21 | -15 | -15 | N/A |
3/31/2019 | 26 | -19 | -18 | -17 | N/A |
12/31/2018 | 21 | -20 | -20 | -19 | N/A |
9/30/2018 | 19 | -22 | -24 | -23 | N/A |
6/30/2018 | 18 | -26 | -27 | -26 | N/A |
3/31/2018 | 18 | -29 | -24 | -23 | N/A |
12/31/2017 | 18 | -31 | -22 | -21 | N/A |
9/30/2017 | 18 | -31 | -21 | -20 | N/A |
6/30/2017 | 17 | -30 | -21 | -21 | N/A |
3/31/2017 | 16 | -29 | -22 | -22 | N/A |
12/31/2016 | 14 | -31 | -25 | -24 | N/A |
9/30/2016 | 13 | -34 | -26 | -26 | N/A |
6/30/2016 | 12 | -37 | -30 | -29 | N/A |
3/31/2016 | 10 | -41 | -35 | -35 | N/A |
12/31/2015 | 10 | -44 | N/A | -36 | N/A |
9/30/2015 | 9 | -49 | N/A | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBII is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MBII is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MBII is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MBII's revenue (25% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: MBII's revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBII's Return on Equity is forecast to be high in 3 years time